29 abril 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Persistence of Severe Pulmonary Hypertension After Transcatheter Aortic Valve Replacement. Incidence and Prognostic Impact

Luca Testa, MD, PhD, Azeem Latib, MD, Federico De Marco, MD, Marco De Carlo, MD, Claudia Fiorina, MD, Rocco Montone, MD, Mauro Agnifili, MD, Marco Barbanti, MD, Anna Sonia Petronio, MD, Giuseppe Biondi Zoccai, MD, Federica Ettori, MD, Silvio Klugmann, MD, Corrado Tamburino, MD, Nedy Brambilla, MD, Antonio Colombo, MD and Francesco Bedogni, MD

Background: Severe pulmonary hypertension (PH) is considered to negatively affect the outcome after transcatheter aortic valve replacement. However, a clear understanding of the pattern, evolution, and clinical impact of different grades of PH in this setting is lacking.

29 abril 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Transcatheter Replacement of Failed Bioprosthetic Valves. Large Multicenter Assessment of the Effect of Implantation Depth on Hemodynamics After Aortic Valve-in-Valve

Matheus Simonato, John Webb, MD, Ran Kornowski, MD, Alec Vahanian, MD, Christian Frerker, MD, Henrik Nissen, MD, Sabine Bleiziffer, MD, Alison Duncan, MD, Josep Rodés-Cabau, MD, Guilherme F. Attizzani, MD, Eric Horlick, MD, Azeem Latib, MD, Raffi Bekeredjian, MD, Marco Barbanti, MD, Thierry Lefevre, MD, Alfredo Cerillo, MD, José María Hernández, MD, Giuseppe Bruschi, MD, Konstantinos Spargias, MD, Alessandro Iadanza, MD, Stephen Brecker, MD, José Honório Palma, MD, Ariel Finkelstein, MD, Mohamed Abdel-Wahab, MD, Pedro Lemos, MD, Anna Sonia Petronio, MD, Didier Champagnac, MD, Jan-Malte Sinning, MD, Stefano Salizzoni, MD, Massimo Napodano, MD, Claudia Fiorina, MD, Antonio Marzocchi, MD, Martin Leon, MD and Danny Dvir, MD

Background: Transcatheter valve implantation inside failed bioprosthetic surgical valves (valve-in-valve [ViV]) may offer an advantage over reoperation. Supra-annular transcatheter valve position may be advantageous in achieving better hemodynamics after ViV. Our objective was to define targets for implantation that would improve hemodynamics after ViV.

27 abril 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement. The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial

Lars Søndergaard, MD, DMSc, Daniel Andreas Steinbrüchel, MD, DMSc, Nikolaj Ihlemann, MD, PhD, Henrik Nissen, MD, PhD, Bo Juel Kjeldsen, MD, PhD, Petur Petursson, MD, PhD, Anh Thuc Ngo, MD, PhD, Niels Thue Olsen, MD, PhD, Yanping Chang, MS, Olaf Walter Franzen, MD, Thomas Engstrøm, MD, DMSc, Peter Clemmensen, MD, DMSc, Peter Skov Olsen, MD, DMSc and Hans Gustav Hørsted Thyregod, MD

Background: The Nordic Aortic Valve Intervention (NOTION) trial was the first to randomize all-comers with severe native aortic valve stenosis to either transcatheter aortic valve replacement (TAVR) with the CoreValve self-expanding bioprosthesis or surgical aortic valve replacement (SAVR), including a lower-risk patient population than previous trials. This article reports 2-year clinical and echocardiographic outcomes from the NOTION trial.

29 abril 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement

Harold L. Dauerman, MD, Michael J. Reardon, MD, Jeffrey J. Popma, MD, Stephen H. Little, MD, João L. Cavalcante, MD, David H. Adams, MD, Neil S. Kleiman, MD and Jae K. Oh, MD

Background: Approximately one third of patients with symptomatic aortic stenosis have reduced left ventricular ejection fraction (LVEF) before transcatheter aortic valve replacement. The incidence, predictors, and significance of early LVEF recovery after CoreValve transcatheter aortic valve replacement have not been described.

16 mayo 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Cardiac Catheterization. Diagnosis of Thin-Capped Fibroatheromas in Intravascular Optical Coherence Tomography Images. Effects of Light Scattering

Jennifer E. Phipps, PhD, Taylor Hoyt, BA, Deborah Vela, MD, Tianyi Wang, PhD, Joel E. Michalek, PhD, L. Maximilian Buja, MD, Ik-Kyung Jang, MD, PhD, Thomas E. Milner, PhD and Marc D. Feldman, MD

Background: Intravascular optical coherence tomography (IVOCT) images are recorded by detecting light backscattered within coronary arteries. We hypothesize that non–thin-capped fibroatheroma (TCFA) causes may scatter light to create the false appearance of IVOCT TCFA.

09 junio 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Artery Disease. Prevalence and Prognostic Significance of Right Ventricular Systolic Dysfunction in Patients Undergoing Transcatheter Aortic Valve Implantation

Alistair C. Lindsay, MD, MBA, PhD, Katie Harron, PhD, Richard J. Jabbour, MD, Ritesh Kanyal, MD, MRCP, Thomas M. Snow, MD, Paramvir Sawhney, MBBS, BA, Francisco Alpendurada, MD, PhD, Michael Roughton, MSc, Dudley J. Pennell, MA, MD, Alison Duncan, MD, PhD, Carlo Di Mario, MD, PhD, Simon W. Davies, MA, MD, Raad H. Mohiaddin, MD, PhD and Neil E. Moat, MBBS, MS

Background: Cardiovascular magnetic resonance (CMR) can provide important structural information in patients undergoing transcatheter aortic valve implantation. Although CMR is considered the standard of reference for measuring ventricular volumes and mass, the relationship between CMR findings of right ventricular (RV) function and outcomes after transcatheter aortic valve implantation has not previously been reported.

26 mayo 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Recanalization of Chronic Total Occlusions in Patients With Previous Coronary Bypass Surgery and Consideration of Retrograde Access via Saphenous Vein Grafts

Rustem Dautov, MD, PhD, Can Manh Nguyen, MD, Omar Altisent, MD, Claire Gibrat, PhD and Stéphane Rinfret, MD, SM

Background: The prevalence of native coronary chronic total occlusions (CTOs) after coronary artery bypass grafts (CABGs) is higher than in non-CABG population. We examined outcomes of CTO percutaneous coronary intervention (PCI) post-CABG versus without CABG. Then, we looked at feasibility and outcomes of retrograde CTO PCI via patent or occluded saphenous vein graft.

25 mayo 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Predictors of Initial Revascularization Versus Medical Therapy Alone in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome Undergoing an Invasive Strategy

Harindra C. Wijeysundera, MD, PhD, Mandeep S. Sidhu, MD, MBA, Maria C. Bennell, MSc, MPH, Feng Qiu, MSc, Dennis T. Ko, MD, MSc, Merril L. Knudtson, MD, Jack V. Tu, MD, PhD and William E. Boden, MD

Background: Although an invasive strategy is a class I clinical practice guideline for non–ST-segment–elevation acute coronary syndromes, there is wide variation in the proportion of patients who undergo revascularization despite early angiography. We sought to identify the predictors of early revascularization versus medical therapy alone in patients with non–ST-segment–elevation acute coronary syndrome undergoing an invasive strategy and to assess their clinical outcomes.

25 mayo 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent. The EGO-Combo Study

Stephen W.L. Lee, MD, Simon C.C. Lam, MD, Frankie C.C. Tam, MD, Kelvin K.W. Chan, MD, Catherine P. Shea, MD, Shun-Ling Kong, MSc(Stat), Anthony Y.T. Wong, MD, Arthur Yung, MD, Lei-Wei Zhang, MD, Hung-Fat Tse, MD, Karl K.Y. Wu, PhD, Raymond Chan, MD, Michael Haude, MD, Roxana Mehran, MD, Gary S. Mintz, MD and Akiko Maehara, MD

Background: Current monotherapy drug-eluting stents are associated with impaired healing, neoatherosclerosis, and late stent thrombosis. The healing profile and neointimal transformation of the first dual-therapy endothelial progenitor cell–capturing sirolimus-eluting stent are unknown.

29 abril 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Structural Heart Disease. Relationship of Annular Sizing Using Multidetector Computed Tomographic Imaging and Clinical Outcomes After Self-Expanding CoreValve Transcatheter Aortic Valve Replacement

Jeffrey J. Popma, MD, Thomas G. Gleason, MD, Steven J. Yakubov, MD, J. Kevin Harrison, MD, John K. Forrest, MD, Brijeshwar Maini, MD, Carlos E. Ruiz, MD, Duane S. Pinto, MD, Marco Costa, MD, Jon Resar, MD, John Conte, MD, Juan Crestanello, MD, Yanping Chang, MS, Jae K. Oh, MD, Michael J. Reardon, MD and David H. Adams, MD

Background: Multidetector computed tomography is useful for determining the appropriate transcatheter heart valve (THV) size in patients with severe aortic stenosis who are suboptimal surgical candidates. The relationship between adherence to the recommended CoreValve sizing algorithm and clinical outcomes is not known.

25 mayo 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Prevalence, Features, and Prognostic Importance of Edge Dissection After Drug-Eluting Stent Implantation. An ADAPT-DES Intravascular Ultrasound Substudy

Nobuaki Kobayashi, MD, PhD, Gary S. Mintz, MD, Bernhard Witzenbichler, MD, D. Christopher Metzger, MD, Michael J. Rinaldi, MD, Peter L. Duffy, MD, MMM, Giora Weisz, MD, Thomas D. Stuckey, MD, Bruce R. Brodie, MD, Rupa Parvataneni, MS, Ajay J. Kirtane, MD, SM, Gregg W. Stone, MD and Akiko Maehara, MD

Background: Intravascular ultrasound detects stent edge dissections after percutaneous coronary intervention that are not seen angiographically. This study investigated the association between stent edge dissections and clinical outcomes.

31 mayo 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Interventions. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. The SORT OUT VII Trial

Lisette Okkels Jensen, MD, DMSci, PhD, Per Thayssen, MD, DMSci, Michael Maeng, MD, PhD, Jan Ravkilde, MD, DMSci, Lars Romer Krusell, MD, Bent Raungaard, MD, PhD, Anders Junker, MD, PhD, Christian Juhl Terkelsen, MD, DMSci, PhD, Karsten Tange Veien, MD, Anton Boel Villadsen, MD, Anne Kaltoft, MD, PhD, Hans-Henrik Tilsted, MD, Knud Nørregaard Hansen, MD, Jens Aaroe, MD, Steen Dalby Kristensen, MD, DMSci, Henrik Steen Hansen, MD, DMSci, Svend Eggert Jensen, MD, PhD, Morten Madsen, MSc, Hans Erik Bøtker, MD, DMSci, PhD, Klára Berencsi, MD, MSc, Jens Flensted Lassen, MD, PhD and Evald Høj Christiansen, MD, PhD

Background: Coronary drug-eluting stents with biodegradable polymers have been designed to improve safety and efficacy.

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease. A Meta-Analysis of Randomized Trials

Giuseppe Ferrante, MD, PhDa; Sunil V. Rao, MDb; Peter Jüni, MDc; Bruno R. Da Costa, MSc, PhDd; Bernhard Reimers, MDa; Gianluigi Condorelli, MD, PhDa,e; Angelo Anzuini, MDf; Sanjit S. Jolly, MD, MScg; Olivier F. Bertrand, MD, PhDh; Mitchell W. Krucoff, MDb; Stephan Windecker, MDi; Marco Valgimigli, MD, PhDi

Objectives: The aim of this study was to provide a quantitative appraisal of the effects on clinical outcomes of radial access for coronary interventions in patients with coronary artery disease (CAD).

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation. The IVUS-XPL Randomized Clinical Trial

Sung-Jin Hong, MDa,b; Dong-Ho Shin, MD, MPHb; Jung-Sun Kim, MDb; Byeong-Keuk Kim, MDb; Young-Guk Ko, MDb; Donghoon Choi, MDb; Ae-Young Her, MDc; Yong Hoon Kim, MDc; Yangsoo Jang, MDb,d,e; Myeong-Ki Hong, MDb,d,e

Objectives: The aim of this study was to investigate whether a 6-month dual-antiplatelet therapy (DAPT) duration was comparable with a 12-month duration in patients who underwent everolimus-eluting stent implantation.

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention. The ADAPT-DES Study

Sorin J. Brener, MDa; Ajay J. Kirtane, MD, SMb,c; Thomas D. Stuckey, MDd; Bernhard Witzenbichler, MDe; Michael J. Rinaldi, MDf; Franz-Josef Neumann, MDg; D. Christopher Metzger, MDh; Timothy D. Henry, MDi,j; David A. Cox, MDk; Peter L. Duffy, MD, MMMl; Ernest L. Mazzaferri, Jr., MDm; Roxana Mehran, MDb,n; Rupa Parvataneni, MSb; Bruce R. Brodie, MDd; Gregg W. Stone, MDb,c

Objectives: The aim of this study was to understand the impact of the timing of ischemic and hemorrhagic events after percutaneous coronary intervention (PCI) with drug-eluting stents on subsequent mortality.